Why the study?
Real-world data on the impact of advances in risk-adjusted management on the outcome of patients with pulmonary embolism are limited.
How have temporal trends in risk-adjusted management impacted in-hospital adverse outcomes and 1-year mortality in patients with pulmonary embolism?
How have temporal trends in risk-adjusted management impacted in-hospital adverse outcomes and 1-year mortality in patients with pulmonary embolism?
In-hospital adverse outcomes and 1-year mortality for pulmonary embolism have remained stable over an 8-year period despite shifts toward shorter hospital stays, more early discharges, and increased NOAC use.
Answers are grounded in this paper and cite their sources.
Stable PE outcomes amid shorter stays and rising NOAC use support safety; leaves open causal effects in observational data.
BACKGROUND: Real-world data on the impact of advances in risk-adjusted management on the outcome of patients with pulmonary embolism (PE) are limited. METHODS: To investigate temporal trends in treatment, in-hospital adverse outcomes and 1-year mortality, we analysed data from 605 patients [median age, 70 years (IQR 56-77) years, 53% female] consecutively enrolled in a single-centre registry between 09/2008 and 08/2016. RESULTS: Over the 8-year period, more patients were classified to lower risk classes according to the European Society of Cardiology (ESC) 2014 guideline algorithm while the number of high-risk patients with out-of-hospital cardiac arrest (OHCA) increased. Although patients with OHCA had an exceptionally high in-hospital mortality rate of 59.3%, the rate of PE-related in-hospital adverse outcomes (12.2%) in the overall patient cohort remained stable over time. The rate of reperfusion treatment was 9.6% and tended to increase in high-risk patients. We observed a decrease in the median duration of in-hospital stay from 10 (IQR 6-14) to 7 (IQR 4-15) days, an increase of patients discharged early from 2.1 to 12.2% and an increase in the use of non-vitamin K-dependent oral anticoagulants (NOACs) from 12.6 to 57.2% in the last 2 years (09/2014-08/2016) compared to first 6 years (09/2008-08/2014). The 1-year mortality rate (16.9%) remained stable throughout the study period. CONCLUSION: In-hospital adverse outcomes and 1-year mortality remained stable despite more patients with OHCA, shorter in-hospital stays, more patients discharged early and a more frequent NOAC use.
No takes yet. Share an insight, caveat, or question.
Ebner et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: